CliffBio
small molecule

AZEDRA

IOBENGUANE I-131

Loss of exclusivity—loss of exclusivity
CompanyProgenics Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZEDRA
Active ingredientIOBENGUANE I-131
Strength15mCi/ML
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusDISCN

More from Progenics Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.